Intranasal Drug Delivery - Global Strategic Business Report

Description:
This report analyzes the US market for Intranasal Drug Delivery in US$ Million by the following Therapeutic Areas: Allergic Infections, Analgesics, Osteoporosis, and Vaccinations. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for this market. Market data and analytics are derived from primary and secondary research.

Company profiles are primarily based on public domain information including company URLs. The report profiles 59 companies including many key and niche players such as -

- Aegis Therapeutics LLC
- AptarGroup, Inc.
- AstraZeneca Plc
- Becton Dickinson and Company
- GlaxoSmithKline Plc

Contents:

INTRANASAL DRUG DELIVERY

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definition and Scope of Study

II. A US MARKET REPORT

1. INDUSTRY OVERVIEW
Prelude
Intranasal Cavity: An Attractive Drug Delivery Route to Cross the Blood Brain Barrier
Bioavailability: An Important Facet of Intranasal Drug Delivery
Chemical Modification
Transient Modification & Limited Enzymatic Activity
Bioavailability of Large Molecules
Bio-Adhesive Polymers: Useful in Increasing Drug Absorption
Outlook
Nasal Drug Delivery Devices & Equipment
Preservative Free Systems (PFS)
Traditional Vs. Advanced Intranasal Drug Formulation Types
Type of Nasal Delivery Vehicles with Select Therapeutic Agents and Area of Application

2. MARKET DRIVERS, TRENDS & ISSUES
Burgeoning Geriatric Populace Spurs Growing Demand for Intranasal Drug Therapies
Table 1: Global Population Estimates (in Billion): 2000-2050P (includes corresponding Graph/Chart)
Table 2: Aging (65+) Demographics as a Percentage of Total Population for Major Countries: 2000, 2011, and 2020 (includes corresponding Graph/Chart)
Table 3: Global Aging Population (in Thousands) by Age Group: 1975, 2000, 2025, and 2050 (includes corresponding Graph/Chart)
Table 4: Global Population Statistics for the 65+ Age Group (Male & Female) for Major Countries/Regions: 2013 (includes corresponding Graph/Chart)
Table 5: Global Life Expectancy at Age 60 and 80 Years: 2010-2015; 2020-2025; and 2045-2050 (includes corresponding Graph/Chart)
Table 6: Life Expectancy for Select Countries in Number of Years: 2015E (includes corresponding Graph/Chart)
Table 7: US Geriatric Population by Age Group (2000, 2010, 2020, 2030 & 2050): Percentage Share of US Population of Senior Citizens of Age Group 65-75 Years, 75-84 Years, and 85 Years and Above (includes
Nasal Drug Delivery Offers New Opportunities for Drug Developers as Patent Cliffs Usher in Dusk of Blockbuster Era

Table 8: Top Nasal Inhalers, Sprays, and Drops Brands in the US (2015): Percentage Share Breakdown of Dollar Sales for Afrin, Afrin No Drip, Arm & Hammer Simply Saline, Neilmed Sinus Rinse, Vicks Sinex, Zicam, Private Labels, and Others (includes corresponding Graph/Chart)

Pharmaceutical and Medical Device Companies Vying to Develop New Intranasal Therapeutics for Allergic Rhinitis Patients

Table 9: Prevalence Percentage of COPD, Asthma, and Allergic Rhinitis for Select Countries: 2016E (includes corresponding Graph/Chart)

Table 10: The US Allergic Rhinitis Patient Population by Disease Severity (2015): Percentage Breakdown of Patient Pool for Mild Intermittent, Mild Persistent, Moderate-severe Intermittent, and Moderate-severe Persistent (includes corresponding Graph/Chart)

The US FDA Approved Intranasal Corticosteroids (INAC) and Intranasal Antihistamines (INAH) for Treating Allergic Rhinitis

US FDA Approved Nasal Spray Medication Types (excluding INAC & INAH) for Allergic Rhinitis Treatment

Intranasal Corticosteroids

A Potential Treatment for Debilitating Chronic Rhinosinusitis Disease

Select Intranasal Corticosteroid Brands for Adult and Pediatric Usage

Select Intranasal Corticosteroids in Pipeline Indicated for Treating Allergic Rhinitis: 2015

Self-Administration of Drugs Brings Intranasal Drug Delivery into the Spotlight

Innovation in Drug Delivery: A Talisman for Success

Active Pharmaceutical Ingredients Used in Formulations for Nasal Drug Delivery with Related Indications

Controlled Release Technology Is the Buzz Word

Target-Specific Delivery Devices: Of Critical Value

Safety and Cost: Primary Growth Drivers

Increasing R&D Unlocks New Therapeutic Areas for Nasal Drug Delivery

Intranasal Therapeutics Delivery

A High Potential Method for Treating CNS Diseases

Intranasal Insulin Delivery Offers Strong Clinical Significance

Intranasal Delivery of Anti-emetic Agent Metoclopramide Hydrochloride Validated by Study on Rodents

Intranasal Delivery of Peptide-Based Pharmaceuticals

Select Protein, Peptide & Non-Peptide Drugs Available as Nasal Spray Solutions in the Marketplace

Tight Junction Biology: A Key Speed Breaker in Commercialization

RNA Interference (RNAi): A Tool to Manipulate Tight Junctions

Research Studies Authenticate Benefits of Bi-Directional Nasal Drug Delivery

Growing Interest for Preservative-free Nasal Spray Formulations

Multi-Dose Containers Developed to Offer Resistance against Microbial Contamination

3. RECENT RESEARCH & DEVELOPMENT INITIATIVES

Intranasal Administration of ATX-LIPO for Brain Targeting

A Promising Therapy for ADHD

Noteworthy Registered and Published Clinical Trials on Intranasal Psychotropics

Focused Ultrasound Leveraged to Enhance Intranasal Drug Delivery

Evoke Pharma Develops EVK-001 Intranasal Metoclopramide Delivery System for Treating Gastroparesis

Smart Polymers with Temperature, pH or Ionic Response in Nasal drug Delivery

Chitosan Thermosensitive Biogels Evaluated for Intranasal Delivery of CNS Drugs

Select Nasal Drug Absorption Enhancers and Related Mechanisms

Dendrimers to Enhance Water-solubility of Antipsychotic Drugs for Intranasal Administration

Naloxone Hydrochloride Nasal Sprays Provides a Powerful Alternative for Opioid Overdose Medications

OptiNose ONZETRA Xsail (AVP-825)

An Innovative Breath- Powered Intranasal Delivery System for Migraine Treatment

Clinical Study Demonstrates Faster Antidepressive Effects of Intranasal Ketamine

Intranasal Aerosol Dose of PH94B Investigated for Treating Social Anxiety Disorder (SAD)

4. TECHNOLOGY OVERVIEW

Intranasal Drug Delivery: A Descriptive Exposition
Nasal Physiology
Challenges Involved In Formulating Nasal Drugs
The Importance of Bioadhesion
Overview of the Traditional Drug Administration Routes, Molecular Weight Capabilities, and Dosage Range
Intranasal Drugs
Prescription (Rx) and Over-the-Counter (OTC)
Differences between Systemic Delivery and Local Effects
Nasal Powders Vs. Sprays
Nasal Drug Delivery Devices
Types of Drug Delivery Devices
Droppers
Sprays
Aerosol Containers/Inhalers
Pumps
Nasal Aspirator
Intranasal Drug Delivery Vis-à-vis Other Delivery Techniques
Limitations of Intranasal Drug Delivery
Allergy
Definition
Symptoms
Allergic Rhinitis
Nasal Allergies

5. NASAL DRUGS: AN OVERVIEW
Nasal Drugs for Allergies
Corticosteroid Nasal Sprays
Flonase
Patanase
Beconase
Other Nasal Corticosteroid Drugs
Antihistamine Nasal Sprays
Astelin Nasal Spray
Otrivin Nasal Spray
Livostin Nasal Spray
Other Nasal Antihistamine Drugs
Select Brands of Allergy Relievers
Nasal Drugs for Postmenopausal Osteoporosis
Calcitonin-Salmon Nasal Spray
Miacalcin Nasal Spray
Fortical® Nasal Spray
Intranasal Pain Management Drugs
Stadol Nasal Spray
Imitrex
Migranal
Zolmitriptan Nasal Spray
Intranasal Analgesics for Treating Migraine
Intranasal Vaccination
Process of Intranasal Immunization
“LAIV” Nasal Spray Flu Vaccine
FluMist® Vaccine from MedImmune
Intranasal Drugs for Sexual Dysfunction
Nasal Spray for Treating Vitamin B12 Deficiency
Nasal Spray for Aiding Smoking Cessation

6. PRODUCT DEVELOPMENTS, APPROVALS & INTRODUCTIONS
Nemera Launches Advancia Multi-Dose Nasal Spray System
Adapt Pharma Launches Narcan Opioid Antagonist
Apotex Unveils Generic Version of Nasonex®
McNeil Consumer Healthcare Rolls Out OTC RHINOCORT®
Cipla Introduces Triamist Intranasal Corticosteroid
OptiNose Bags FDA Approval for ONZETRA™ Xsail™
Avanir's Onzetra Secures FDA Approval
FDA Approves Lannett's Sumatriptan Nasal Spray
Meda’s Dymista Bags Health Canada’s Approval
Endo Pharmaceuticals Announces Availability of NATESTO
AstraZeneca Canada Unveils FluMist for Children
Perrigo Receives US FDA Approval for Generic Version of Sun Pharma’s Kenalog
GSK Rolls Out OTC Version of Flonase Allergy Relief
Upsher-Smith Publishes Data from USL261 Phase 1 Trials
KemPharm Concludes KP201/APAP’s Human Abuse Liability Program
OptiNose Publishes Results of OPN 375’s Phase III Trial
NanoBio’s Genital Herpes Vaccine Proven Effective
Recro Pharma Releases Further Details of Dex-IN’s Phase II Clinical Trial
Evoke Announces Phase III Trials of EVK-001
FDA Accepts Filing of TARSA’s TBRIA
FDA Accepts Review of Pfizer’s ALO-02
Breckenridge Bags FDA Approval for Azelastine HCI Nasal Solution
ZOMIG® Gets FDA Approval
Sandoz Introduces Generic Version of Novartis NASONEX
Chattem Releases OTC NASACORT® ALLERGY 24HR NASAL SPRAY
FDA Approves QNASL Nasal Aerosol

7. RECENT INDUSTRY ACTIVITY
Egalet Inks Deal With Septodont for SPRIX® Promotion
Lilly Acquires Intranasal Glucagon Rights
UAE recalls Otrivin Nasal Spray Batches
Eli Lilly Acquires Rights for Innoven't Intranasal Glucagon
AstraZeneca Commences Shipment of FluMist®
ProStrakan Concludes Archimedes Acquisition
Neurelis Inks Deal with Biotie Therapies
AntiOp Signs Pact for Developing Intranasal Naloxone
Depomed Acquires Lazanda® Nasal Spray
Novartis, Sandoz and Apotex Withdraws Synthetic Calcitonin Nasal Spray Products
Retrophin Inks Deal for Syntocinon Nasal Spray

8. FOCUS ON SELECT GLOBAL PLAYERS
Aegis Therapeutics LLC (USA)
AptarGroup, Inc. (USA)
AstraZeneca Plc. (UK)
MedImmune, Inc. (USA)
Becton Dickinson and Company (USA)
GlaxoSmithKline Plc. (UK)
Johnson & Johnson Inc. (USA)
Marina Biotech, Inc. (USA)
Merck & Co., Inc. (USA)
Nemera (France)
Novartis AG (Switzerland)
Optinose US Inc. (USA)
Pfizer, Inc. (USA)
Valeant Pharmaceuticals International Inc. (Canada)

9. US MARKET ANALYTICS
Table 12: The US Recent Past, Current & Future Analysis for Intranasal Drug Delivery Therapeutics by Therapeutic Area
Allergic Infections, Analgesics, Osteoporosis, and Vaccinations Markets Independently Analyzed by Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 13: The US Historic Review for Intranasal Drug Delivery Therapeutics by Therapeutic Area
Allergic Infections, Analgesics, Osteoporosis, and Vaccinations Markets Independently Analyzed by Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 14: The US 14-Year Perspective for Intranasal Drug Delivery by Therapeutic Area
Percentage Breakdown of Values Sales for Allergic Infections, Analgesics, Osteoporosis, and Vaccinations for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

III. COMPETITIVE LANDSCAPE
Total Companies Profiled: 59 (including Divisions/Subsidiaries 79)
The United States (49)
Canada (6)
Japan (1)
Europe (18)
- France (2)
- Germany (4)
- The United Kingdom (7)
- Rest of Europe (5)
Asia-Pacific (Excluding Japan) (3)
Latin America (1)
Middle-East (1)

Ordering:
Order Online - http://www.researchandmarkets.com/reports/516888/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

- **Product Name:** Intranasal Drug Delivery - Global Strategic Business Report
- **Web Address:** [http://www.researchandmarkets.com/reports/516888/](http://www.researchandmarkets.com/reports/516888/)
- **Office Code:** SCG3I8GX

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF)</td>
<td>USD 4500</td>
<td></td>
</tr>
<tr>
<td>Single User</td>
<td>USD 6300</td>
<td></td>
</tr>
<tr>
<td>1 - 5 Users</td>
<td>USD 8550</td>
<td></td>
</tr>
<tr>
<td>1 - 10 Users</td>
<td>USD 10800</td>
<td></td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in **BLOCK CAPITALS**

- **Title:** Mr ☐ Mrs ☐ Dr ☐ Miss ☐ Ms ☐ Prof ☐
- **First Name:** __________________________
- **Last Name:** ____________________________
- **Email Address:** * ______________________
- **Job Title:** ____________________________
- **Organisation:** _________________________
- **Address:** ______________________________
- **City:** _________________________________
- **Postal / Zip Code:** ______________________
- **Country:** ______________________________
- **Phone Number:** _________________________
- **Fax Number:** __________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp